Lipocalin-2 (LCN2/NGAL): Bone-Derived Appetite Suppressor via MC4R and Adipose-Derived Pro-Inflammatory Adipokine in Metabolic Research

# Lipocalin-2 (LCN2/NGAL): Bone-Derived Appetite Suppressor via MC4R and Adipose-Derived Pro-Inflammatory Adipokine in Metabolic Research

Lipocalin-2, also known as neutrophil gelatinase-associated lipocalin (NGAL) or 24p3 or siderocalin, is a 25-kDa member of the lipocalin superfamily of hydrophobic ligand-binding proteins. It gained prominence in nephrology as a sensitive biomarker of acute kidney injury (AKI), detected in urine within 2 hours of tubular injury — a clinical use that remains its most widely applied measurement. However, the metabolic biology of LCN2 is arguably more scientifically interesting: it functions simultaneously as a bone-derived satiety hormone that activates hypothalamic MC4R to suppress appetite, and as an adipokine/acute phase reactant in obese adipose tissue that promotes insulin resistance and inflammation. This dual role positions LCN2 as a mediator of communication between three tissues — bone, adipose, and hypothalamus — in a circuit that regulates energy homeostasis.

Discovery in Multiple Contexts

LCN2 was independently discovered in several contexts, explaining its multiple names:

1988 — Acute phase protein discovery: LCN2 was identified as a protein induced in livers during acute phase response (fever, inflammation, sepsis). It was initially studied as an inflammatory marker without clear molecular function.

1989 — NGAL identification: Kjeldsen et al. identified the protein as a 25-kDa component of specific secondary granules in human neutrophils, co-purified with neutrophil gelatinase (MMP-9) — hence the NGAL name. NGAL/MMP-9 complexes in neutrophils protect MMP-9 from autodegradation.

1993 — Siderocalin/iron transport role: LCN2 was identified as a bacterial iron sequestration protein — a component of innate immune defense against bacteria. The protein binds ferric iron chelated by bacterial catecholate-type siderophores (enterobactin), preventing bacteria from acquiring iron and thereby inhibiting bacterial growth. This bacteriostatic mechanism is why LCN2 is induced during infection.

2008 — AKI biomarker: Mishra et al. established NGAL/LCN2 as an early urinary and plasma biomarker of acute kidney injury in cardiac surgery patients, preceding creatinine elevation by 24-48 hours.

2017 — Bone-derived appetite suppressor: Mosialou et al. (PMID: 28273060) published in Nature the finding that osteoblast-derived LCN2 is a bone-to-brain hormone that suppresses appetite by binding and activating MC4R in hypothalamic neurons. This discovery reframed the entire biology.

Gene and Protein Structure

LCN2 Gene

The human LCN2 gene is located on chromosome 9q34.11 and encodes a 198-amino acid precursor with a signal peptide (residues 1-20), yielding a 178-amino acid mature protein. The molecular weight is approximately 25 kDa as a monomer, but LCN2 can dimerize (non-covalently) and also forms disulfide-linked dimers (~50 kDa). In complex with MMP-9, it forms the NGAL-MMP-9 heterodimer (~125 kDa) via a non-covalent interaction with a specific site on MMP-9.

LCN2 has the canonical lipocalin fold: an 8-stranded antiparallel β-barrel (calyx) with a hydrophobic interior cavity that binds small lipophilic or amphiphilic ligands. The N-terminal α-helix caps one end of the barrel. The cavity accommodates iron-siderophore complexes (the bacteriostatic function) or fatty acid derivatives and lipid metabolites (the signaling functions).

Post-translational modifications:

• •N-linked glycosylation at Asn63: major determinant of the 25 vs. 23 kDa forms seen on SDS-PAGE
• •The glycan structure varies with cell type and physiological state
• •Iron-loaded LCN2 (bound to iron-siderophore complex) has slightly different pharmacokinetics than apo-LCN2

Bone-Derived Appetite Regulation via MC4R

Discovery of the Bone-Brain-Appetite Axis

1. Osteoblasts (bone-forming cells) express and secrete LCN2 after feeding (post-prandial increase)

2. LCN2 circulates in plasma and enters the brain

3. In the hypothalamus, LCN2 activates MC4R (melanocortin 4 receptor) on PVN and ARC neurons to suppress appetite and reduce food intake

4. Lcn2-knockout mice showed increased food intake and developed obesity despite the absence of adiponectin or leptin deficiency

5. Recombinant LCN2 administration reduced food intake in wild-type and obese mice, including mice resistant to leptin

6. The effect required MC4R — Mc4r-knockout mice were unresponsive to LCN2

7. LCN2 injection increased MC4R signaling (cAMP elevation in hypothalamic neurons), confirming agonist activity

This paper established bone as an endocrine organ for energy balance regulation — a concept that also encompasses osteocalcin (bone-derived hormone promoting testosterone, muscle function, and glucose metabolism, characterized by Gerard Karsenty's group at Columbia). LCN2 completes a dual bone-derived appetite regulation system: post-prandial LCN2 signals satiety; osteocalcin activates β-cell insulin secretion and muscle glucose uptake during exercise.

The MC4R connection is particularly significant because MC4R is one of the most important hypothalamic energy homeostasis receptors: mutations in MC4R cause the most common form of monogenic obesity in humans (POMC-derived α-MSH activates MC4R for satiety; AgRP antagonizes MC4R for hunger). LCN2 as an endogenous MC4R agonist was unexpected, as the receptor was thought to respond only to melanocortin peptides. LCN2 appears to bind MC4R at a different site from α-MSH, suggesting a non-competitive or allosteric interaction.

Post-Prandial Regulation

Osteoblast LCN2 secretion is stimulated by:

• •Feeding (amino acids, particularly glutamate and glutamine)
• •Insulin (post-prandial insulin peak drives osteoblast LCN2 secretion)
• •Glucose

Fasting suppresses osteoblast LCN2 production, while refeeding rapidly restores it. This creates a bone-brain hormonal circuit where feeding stimulates bone LCN2 → hypothalamic MC4R activation → suppression of further feeding, acting as a satiety signal from an unexpected source.

Plasma LCN2 post-prandial kinetics show a peak approximately 30-60 minutes after eating, consistent with a satiety hormone that signals meal termination.

Adipose Tissue and Pro-Inflammatory Functions

In parallel with its bone-derived satiety function, adipose tissue expresses LCN2 as a pro-inflammatory adipokine — a sharp biological contrast that reflects LCN2's multiple cell type-specific roles.

LCN2 as Adipokine

Adipocytes and adipose stromal cells produce LCN2, and this production is markedly upregulated in obese, insulin-resistant adipose tissue:

• •Plasma LCN2 correlates positively with BMI, waist circumference, and visceral adiposity
• •Adipose tissue LCN2 mRNA is elevated in obese vs. lean subjects
• •Free fatty acids (palmitate, oleate) and pro-inflammatory cytokines (TNF-α, IL-1β) dramatically increase LCN2 expression in adipocytes
• •LCN2 promotes adipocyte insulin resistance by activating IKKβ/NF-κB and suppressing IRS-1/Akt insulin signaling
• •LCN2 promotes macrophage infiltration into adipose tissue (by acting as a monocyte chemoattractant)
• •In obese adipose tissue, LCN2 promotes M1 macrophage polarization

The pro-inflammatory adipokine role of LCN2 appears to be directly opposed to its bone-derived satiety function — potentially creating a pathological scenario in obesity where adipose LCN2 and bone LCN2 have conflicting effects on appetite and metabolic homeostasis. However, whether adipose-derived LCN2 reaches the hypothalamus in concentrations sufficient to activate MC4R is unclear; the bone-derived post-prandial pool may be the physiologically relevant appetite-regulatory source.

LCN2 and Iron Metabolism in Adipose Tissue

Beyond its inflammatory role, adipose LCN2 contributes to iron homeostasis in the tissue. LCN2 mediates iron uptake into adipocytes via binding to iron-loaded siderophore complexes and delivering iron through megalin (LRP2) receptor-mediated endocytosis. Adipocytes have significant iron storage capacity, and LCN2-mediated iron uptake may contribute to iron redistribution in obesity-associated iron dysregulation.

Acute Kidney Injury Biomarker Function

The most widely applied clinical use of LCN2/NGAL is as an early AKI biomarker. The biology is straightforward:

1. Proximal tubular cells under stress (ischemia, nephrotoxins, inflammation) dramatically upregulate LCN2 within 2-4 hours

2. LCN2 appears in urine at concentrations detectable by ELISA or lateral flow assay

3. LCN2 also increases in plasma from multiple sources including stressed tubular cells and activated immune cells

Clinical utility: Urinary NGAL >150 µg/g creatinine within 2 hours of cardiac surgery strongly predicts subsequent AKI requiring renal replacement therapy, preceding serum creatinine elevation by 24-48 hours. This early detection window allows earlier nephroprotective interventions.

This AKI biomarker application is clinically validated and FDA-cleared (BioPorto NGAL test, Abbott Diagnostics ARCHITECT NGAL), making LCN2 the most clinically deployed of all the proteins discussed in this article. However, the AKI biology is mechanistically distinct from the appetite regulation and adipokine roles and represents a third independent biological context for LCN2.

Plasma LCN2 in Human Metabolic Disease

Plasma LCN2 (distinct from urinary NGAL) in the metabolic context:

• •Obesity: Positively correlates with BMI; adipose overproduction drives elevation
• •Insulin Resistance: Positive correlation with HOMA-IR; may be causal (LCN2 promotes adipocyte insulin resistance in vitro)
• •Type 2 Diabetes: Elevated in T2DM; inversely correlates with insulin sensitivity
• •Metabolic Syndrome: Elevated; correlates with triglycerides, waist circumference
• •NAFLD: Elevated in NAFLD/NASH; correlates with steatosis grade and fibrosis
• •Cardiovascular Disease: Elevated in CAD and heart failure; LCN2-MMP-9 complex may promote plaque vulnerability

The apparent paradox — LCN2 from bone suppresses appetite and is reduced in obesity, while LCN2 from adipose promotes insulin resistance and is elevated in obesity — means that total plasma LCN2 in obese subjects reflects the dominant adipose-derived contribution, masking any relative deficiency of bone-derived satiety LCN2.

Research Tools and Experimental Systems

Current Research Frontiers

MC4R agonism and obesity treatment: LCN2 as an endogenous MC4R agonist from bone has re-energized interest in MC4R pharmacology. Setmelanotide (a synthetic melanocortin receptor agonist) is FDA-approved for genetic obesity syndromes (POMC deficiency, LEPR deficiency). Whether LCN2 analogs or MC4R-selective agonists based on the LCN2 binding pharmacophore could be developed for broader obesity treatment is an active question.

Osteocalcin + LCN2 combined measurement: Since both osteocalcin and LCN2 are bone-derived hormones with metabolic regulatory functions (osteocalcin promotes testosterone, muscle glucose uptake, memory; LCN2 suppresses appetite via MC4R), combined measurement and understanding of their post-exercise and post-prandial kinetics may reveal a more complete picture of bone endocrinology.

LCN2 in neuroinflammation: LCN2 is produced by reactive astrocytes and microglia during neuroinflammation and has been shown to promote neurodegeneration in some models (Parkinson's disease, multiple sclerosis). This brain-specific biology is distinct from both the bone-appetite and adipokine roles but adds to LCN2's biological complexity.

Therapeutic targeting in sepsis/AKI: The siderocalin/iron-sequestration function makes LCN2 potentially useful as an anti-bacterial therapeutic — delivered exogenously to limit iron availability to pathogens. This application is distinct from all metabolic applications.

Reconciling the bone vs. adipose LCN2 contributions: Development of tissue-specific LCN2 measurements (possibly using mass spectrometry glycoform analysis or proteomics to distinguish glycosylation patterns between bone-derived and adipose-derived LCN2) could separate the beneficial bone endocrine signal from the detrimental adipose inflammatory signal.

Conclusion

Lipocalin-2 is among the most biologically multifaceted proteins in the lipocalin family, simultaneously serving as a bone-derived appetite suppressor (via MC4R), an adipose-derived pro-inflammatory adipokine (contributing to obesity-associated insulin resistance), an acute phase reactant in innate immunity (binding bacterial siderophore-iron complexes), a neutrophil granule component protecting MMP-9, an early AKI biomarker (urinary tubular stress marker), and a neuroinflammatory mediator. The 2016 discovery of LCN2 as a bone-derived MC4R agonist fundamentally repositioned it from a primarily inflammatory marker to a genuine endocrine bone hormone — following the precedent of osteocalcin and establishing bone as a multifunctional endocrine organ. The obesity paradox (bone-derived LCN2 should suppress appetite; adipose-derived LCN2 promotes insulin resistance) may reflect physiological uncoupling in chronic obesity, where adipose LCN2 overproduction dominates while bone-derived post-prandial signaling is insufficient to overcome orexigenic drives. Recombinant LCN2 for MC4R pharmacology, tissue-specific knockout mice, and validated NGAL ELISAs constitute the current research toolkit.

Key References

1. Mosialou I, Shikhel S, Liu JM, et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature. 2017;543(7645):385-390. PMID: 28273060

3. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231-1238. PMID: 15811456

4. Wang Y, Lam KS, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007;53(1):34-41. PMID: 17040956

5. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007;56(10):2533-2540. PMID: 17639021

8. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012;1826(1):129-169. PMID: 22513004

9. Jung TW, Lee MW, Lee YJ, Kim SM. Lipocalin-2 inhibits AMPK signaling and induces insulin resistance. Biochem Biophys Res Commun. 2012;418(3):515-520. PMID: 22249163

10. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432(7019):917-921. PMID: 15531878

---

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. Lipocalin-2/NGAL and related lipocalin proteins are research tools and investigational agents. All research applications must comply with applicable institutional, local, and national regulations.